---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-021314"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-22T23:45:23.794015+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Madrigal Q1 2025 revenue $137.3M from Rezdiffra; 17,000+ patients on therapy

## Summary
- Net Rezdiffra sales of $137.3M in Q1 2025 vs. $0 in prior-year period as first commercial quarter.
- Operating expenses $216.6M (up 42% YoY) driven by SG&A for Rezdiffra launch; R&D fell to $44.2M.
- Cash, equivalents, restricted cash and marketable securities $848.1M at March 31, 2025.
- Appointed David Soergel, M.D. as CMO; Jacqualyn Fouse, Ph.D. to Board of Directors.
- Two-year F4c cirrhosis data from MAESTRO-NAFLD-1 accepted as EASL late-breaker (May 7–10).

## SEC filing metadata
- accession: 0001628280-25-021314
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000162828025021314/0001628280-25-021314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000162828025021314/mdgl-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-021314
- JSON: https://secwatch.observer/filing/0001628280-25-021314.json
- Plain text: https://secwatch.observer/filing/0001628280-25-021314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.